Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Taps Italian Distributor

NEW YORK (GenomeWeb News) – AXA Diagnostics will distribute Rosetta Genomics' microRNA-based miRview line of molecular diagnostic cancer tests in Italy, Rosetta said today.

The exclusive distribution agreement with the Pomezia, Italy-based AXA Diagnostics covers the miRview mets, miRview squamous, and miRview meso tests. AXA will market the tests in Italy, and the samples will be analyzed at Rosetta Genomics' CLIA-certified lab in Philadelphia.

Rosetta Genomics' mets test is used to identify primary tumor site in patients with metastatic cancer and in those with cancer of unknown primary origin. The squamous test differentiates squamous from non-squamous, non-small cell lung cancer patients, and the meso test uses biomarkers to differentiate mesothelioma from other lung carcinomas.

Financial terms of the collaboration were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.